EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study

Miroslav Vujasinovic iD, Fahim Ebrahimi, Bjorn Roelstraete, David Bergman iD, Jiangwei Sun, Omid Sadr-Azodi, J-Matthias Löhr iD, Jonas F Ludvigsson

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.12761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Miroslav Vujasinovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Pancreatic Diseases, Fatty Liver, Pancreatitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Crohnâ€s and Colitis Organisation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Ruth och Richard Julins Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been linked to pancreatic diseases, but evidence from population‐based studies with liver histology is lacking. Aims and methods In this population‐based cohort including all Swedish adults ( n = 8563) with biopsy‐proven MASLD, we aimed to investigate incidences of pancreatic diseases compared with matched reference individuals from the general population ( n = 38,858) and full siblings ( n = 6696). Using Cox proportional hazard models, we calculated multivariable adjusted hazard ratios (aHRs) and confidence intervals (CIs).

Results

We documented 359 incidents of pancreatic diseases in MASLD patients and 880 events in matched reference individuals, resulting in an incidence rate difference of 1.54 (95% CI, 1.25–1.84). The relative risk of pancreatic disease was highest in the first two years after MASLD diagnosis (aHR, 2.19 [95% CI, 1.92–2.50), but remained statistically significant increased even up to ten years [aHR, 1.60 (95% CI, 1.38–1.85)]. The most common pancreatic disease in individuals with MASLD was acute non‐biliary pancreatitis (1.44 vs. 0.44 events/1000 PY), followed by chronic pancreatitis (0.54 vs. 0.12/1000 PY) and pancreatic cancer (0.88 vs. 0.47/1000 PY). We documented 130 versus 344 pancreas‐related deaths among individuals with MASLD and their matched comparators, yielding an absolute risk difference of 0.51/1000 PY and an aHR of 2.41 (95%CI = 1.95−2.97). The findings were consistent in sibling‐controlled analyses with an aHR of 2.21 (95%CI = 1.69–2.90).

Conclusions

MASLD was associated with significantly higher rates of acute and chronic pancreatitis of predominantly non‐biliary origin, as well as an increased risk of pancreatic cancer and pancreas‐related mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic DiseasesFatty LiverPancreatitisHumansMaleFemaleSwedenMiddle AgedAdultIncidenceSiblingsAgedCase-Control StudiesRisk FactorsProportional Hazards ModelsCohort StudiesPancreatic Neoplasms

Stichwörter der Autor:innen

acute pancreatitischronic pancreatitismetabolic dysfunction‐associated steatotic liver diseasepancreatic cancer

Autor:innen und Institutionen

  • Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel-Clarunis, Basel, Switzerland.
  • Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Unit of Upper Gastrointestinal Surgery, Saint Göran's Hospital, Stockholm, Sweden.

ORCID-Profile: Miroslav Vujasinovic, David Bergman, J-Matthias Löhr

Förderung

  • European Crohnâ€s and Colitis Organisation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Ruth och Richard Julins Stiftelse
  • Mag-TarmFonden, Swedish Gastroenterology Society

Zitieren

APA

Vujasinovic, M., Ebrahimi, F., Roelstraete, B., Bergman, D., Sun, J., Sadr-Azodi, O., Löhr, J. M., & Ludvigsson, J. F. (2025). Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12761

Vancouver

Vujasinovic M, Ebrahimi F, Roelstraete B, Bergman D, Sun J, Sadr-Azodi O, et al. Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12761

BibTeX
@article{Vujasinovic2025,
  author = {Vujasinovic, Miroslav and Ebrahimi, Fahim and Roelstraete, Bjorn and Bergman, David and Sun, Jiangwei and Sadr-Azodi, Omid and Löhr, J-Matthias and Ludvigsson, Jonas F},
  title = {Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.12761}
}
Kostenlos starten →